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Abstract 
There is growing evidence of the protective role of the Mediterranean diet (MD) on cancer. 
However, no prospective study has yet investigated its influence on lymphoma. We evaluated the 
association between adherence to the MD and risk of lymphoma and its subtypes in the 
European Prospective Investigation into Cancer and Nutrition (EPIC) study. The analysis included 
476,160 participants, recruited from ten European countries between 1991 and 2001.  Adherence 
to the MD was estimated through an adapted relative Mediterranean diet (arMED) score 
excluding alcohol. Cox proportional hazards regression models were used while adjusting for 
potential confounders. During an average follow-up of 13.9 years, 3,136 lymphomas (135 
Hodgkin lymphoma (HL), 2,606 non-Hodgkin lymphoma and 395 lymphoma NOS) were 
identified. Overall, a 1-unit increase in the arMED score was associated with a 2% lower risk of 
lymphoma (95% CI: 0.97; 1.00, p-trend=0.03) while a statistically non-significant inverse 
association between a high versus low arMED score and risk of lymphoma was observed (HR: 
0.91 (95% CI 0.80; 1.03), p-trend=0.12). Analyses by lymphoma subtype did not reveal any 
statistically significant associations. Albeit with small numbers of cases (N= 135), a suggestive 
inverse association was found for HL (HR 1-unit increase= 0.93 (95% CI: 0.86; 1.01), p-
trend=0.07). However, the study may have lacked statistical power to detect small effect sizes for 
lymphoma subtype. Our findings suggest that an increasing arMED score was inversely related to 
the risk of overall lymphoma in EPIC, but not by subtypes. Further large prospective studies are 
warranted to confirm these findings.  
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1. Introduction 
Lymphomas are a heterogeneous group of malignancies particularly prevalent in Western 
countries. Although some lymphoid neoplasms have been consistently linked to certain infections 
and severe immunosuppression, their etiology remains elusive, and evidence from epidemiologic 
studies increasingly points to etiologic heterogeneity among subtypes1.  
An increase in the incidence of lymphoma has been observed in many regions during the last 
decades2, and a change in lifestyle might be one possible explanation for this pattern. However, 
there is limited evidence regarding extrinsic-risk factors, particularly diet, and lymphoma risk3,4. In 
the recently released Third Expert Report on ‘Diet, Nutrition, Physical Activity, and Cancer’ by the 
World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR)5, no 
conclusive associations for specific dietary factors and hematological malignancies were 
reported. Studies from the European Prospective Investigation into Nutrition and Cancer (EPIC) 
study have neither shown consistent associations between consumption of meat and dairy6 nor 
vegetables7 and overall lymphoma risk, although some statistically significant associations were 
seen for several lymphoma subtypes.   
There is evidence that the Mediterranean diet (MD) has a protective role on risk of overall8 and 
specific types of cancer9, such as breast10, colorectal11 or gastric cancers12. However, 
epidemiological research into the effect of a MD pattern on lymphoma remains limited. To our 
knowledge, no study has yet evaluated the influence of validated a priori MD score on lymphoma 
risk, while studies on a posteriori healthy-like dietary patterns have yielded inconsistent results for 
overall lymphoma as well as its subtypes13–15. 
The aim of this study is to investigate the association between adherence to the Mediterranean 
dietary pattern and lymphoma risk within the EPIC population. The EPIC study provides the 
opportunity to examine this relation in a prospective design and within a European population with 
a wide spectrum of dietary habits. 
 
2. Material and Methods 
 
Study population  
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EPIC is a large prospective cohort study designed to investigate the relationship between diet, 
lifestyle, environmental factors and cancer. The rational, full methods and study design have 
been described previously16,17. In brief, 521,324 subjects, mostly aged 30 to 70 years, were 
recruited between 1992-2000 in 23 centers from ten European countries (Denmark, France, 
Germany, Greece, the Nederland’s, Italy, Norway, United Kingdom, Spain and Sweden). The 
ethical review boards from the International Agency for Research on Cancer (IARC) and all local 
participating centers approved the study, and all participants gave their informed consent.  
Of the 521,324 EPIC cohort participants, we excluded prevalent cancer cases (n= 25,184), 
subjects with missing follow-up information (n= 4,148), with incomplete/ no dietary information (n= 
6,259), or those in the highest and lowest 1% of the distribution for the ratio of energy intake to 
estimate energy requirement (n= 9,573). Therefore, the current analysis was based on 476,160 
subjects among whom 3,136 incident lymphoma cases occurred. 
Data collection 
Validated country-specific questionnaires were used to record the usual diet during the previous 
year17,18; namely through quantitative or semi-quantitative food frequency questionnaires (FFQs) 
(administered through a personal interview or self-administered), although few countries used 
semi-quantitative FFQs combined with a food record. Lifestyle questionnaires were used to obtain 
information on sociodemographic characteristics, physical activity, reproductive history, use of 
oral contraceptives and hormone replacement therapy, medical history and alcohol and tobacco 
consumption. Anthropometric measures were also ascertained at recruitment. 
Exposure assessment – arMED 
The level of adherence to the MD was assessed using the adapted relative MD (arMED) score10, 
which  excludes alcoholic beverages as they have been inversely associated with several 
lymphoma subtypes19. The scoring system, adapted from the original index designed by 
Trichopoulou et al.20, has been detailed previously12. In brief, the arMED is a 16-point linear score 
that incorporates eight key dietary components: six components presumed to reflect the MD [fruit 
(including nuts and seeds), vegetables, legumes, fish (including seafood), olive oil and cereals] 
and two components consumed in low quantity in the MD (dairy products and meat). Intake of 
each component was calculated as a function of energy density (g/day/1000kcal) and divided into 
tertiles (estimated using the overall study population). A score of 0 to 2 was assigned for the first, 
second and third tertile of intakes for the components presumed to fit the MD, while the scoring 
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was inverted for the components presumed to not fit the MD (giving a lower score for higher 
intakes). The scoring for olive oil was adapted owing the low consumption of non-Mediterranean 
countries, by assigning 0 to non-consumers, 1 for subjects below the median and 2 for subjects 
equal or above this median (the median was calculated using the overall study population and 
considering only consumers). The points were summed to define the arMED score, that ranged 
from 0 to 16 (from the lowest to the highest adherence), and was in turn divided into three 
categories: low (0-5), medium(6-9) and high(10-16) as described previously12.  
Follow-up and outcome assessment 
Incident lymphoma cancer cases were identified by population cancer registries for Denmark, 
Italy, the Netherlands, Norway, Spain, Sweden and the United Kingdom. A combination of 
methods was used in France, Germany and Greece, including cancer and pathology registries, 
health insurance records, and active follow-up contacting participants or their next-of-kin. 
Mortality data were also obtained from regional or national mortality registries. The follow-up 
period was defined from the age at recruitment to the age at first cancer diagnosis, death or last 
complete follow-up, depending on which occurred first. Censoring dates for the last complete 
follow-up ranged from June 2008 to December 2013, depending on the EPIC center. 
Initially, the diagnosis of lymphoma cases was based on the second revision of the International 
Classification of Diseases for Oncology (ICD-O-2). Later, all cases were reclassified into the ICD-
O-3, using a conversion program available on the web site of the Surveillance Epidemiology and 
End Results (SEER) program (http://seer.cancer.gov/tools/conversion/ICD02- 3manual.pdf) and 
involving a pathology expert and experts from the EPIC centers. Because not all ICD-O-2 
diagnostics can be translated unequivocally into the current classification, we left the respective 
lymphomas unclassified (not otherwise specified ‘‘NOS’’) when further detailed specification 
failed. Finally, the InterLymph Pathology Working Group classification, which is based in the 2008 
WHO classification, was used to categorize lymphoma histologic subtypes1.  
In the current analysis, the following groups were considered: Hodgkin lymphoma (HL) and non-
Hodgkin lymphoma (NHL); within NHL, mature B-cell lymphoma and mature T/NK-cell lymphoma; 
and among mature B-cell lymphoma, the following entities: diffuse large B-cell lymphoma 
(DLBCL), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL) (including small 
lymphocytic leukemia), multiple myeloma/plasma cell neoplasm (MM/PCN), and other B-cell 
lymphoma (i.e. those cases in which the B-cell lymphoma subtype is unknown or does not fall 
9 
 
within the above mentioned subtypes). Other entities were not considered due to small numbers 
(Table 1). 
Statistical analysis 
Cox proportional hazard models were used to estimate the hazard ratio (HR) and 95% confidence 
intervals (CI) of the association between the arMED score and lymphoma risk. The arMED score 
was analyzed both as a continuous variable (per 1-unit increase) and as a categorical variable 
(low, medium and high level of adherence). In addition, Cox models were fitted with the arMED 
ordinal variable as continuous to test for linear trend for comparison with published literature on 
solid cancers. Two models with two levels of adjustment were used: a basic model, stratified by 
center, sex and age at recruitment (in 1-year categories) and a multivariable model, further 
adjusted for body mass index (BMI) (<25, 25-30, ≥30 kg/m2), total energy intake (continuous, 
kcal/day), educational level (no formal education, primary school, secondary school, technical or 
professional training, University, unknown [3.6%]), height (continuous, cm), physical activity level 
based on the Cambridge physical activity index (inactive, moderately inactive, moderately active, 
active, unknown [1.9%]), smoking status (never, former, current and, unknown [2.0%]), and 
alcohol intake at recruitment (continuous, g/day). We tested for interaction by age, sex, alcohol 
intake and smoking by including a cross-product term along with the armed score (continuous) in 
the multivariable Cox model. The statistical significance of the cross-product term was evaluated 
using likelihood ratio test.  
Sensitivity analyses were performed by repeating main Cox analyses (i) including alcohol in the 
score computation, ii) censoring participants and excluding cases with less than two years of 
follow-up (n=259 cases), (iii) excluding participants without complete data (n=226 cases), and (iv) 
restricting HL analysis to classical HL cases. Schoenfeld residuals were used to ensure that the 
proportional hazard assumption was met in all models. Two-sided p-values were reported with 
statistical significance set at p<0.05. All analyses were performed by using STATA statistical 
software, version 14 (Stata Corporation, College Station, Texas).  
3. Results 
During an average follow-up of 13.9 years, 3,136 lymphoma cases (2,606 NHL, 135 HL and 395 
lymphoma NOS) were diagnosed. A detailed distribution of cases by lymphoma subtype and 
country is displayed in Table 1. As expected, the highest levels of the arMED score were found in 
Mediterranean regions (i.e. Greece, Spain and Italy), while the lowest scores were found in 
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Sweden, the Netherland’s and Denmark. Baseline characteristics of the study participants 
according to category of the arMED score are shown in Table 2. In general, participants with a 
higher arMED score were more likely to be women, slightly younger, never smokers, physically 
inactive, and to have a higher educational level and lower alcohol intake compared to those with 
a low arMED score. 
Table 3 shows basic and multivariable HR estimates for category of arMED score associated with 
lymphoma risk, overall and by subgroups. Overall, a 1-unit increase in the arMED score was 
associated with a 2% lower risk of lymphoma (95% CI: 0.97; 1.00, p-trend=0.03) while a 
statistically non-significant inverse association between a high versus low arMED score and risk 
of lymphoma was observed (HR: 0.91 (95% CI 0.80; 1.03), p-trend=0.12). No statistically 
significant associations were observed between the arMED score and HL, NHL or any NHL 
subtypes. However, albeit with smaller numbers of cases, the lowest HR were observed for HL 
(HRhigh vs. low=0.64 (95% CI: 0.34; 1.19), p-trend=0.16; HR1-unit increase=0.93 (95% CI: 0.86; 1.01), p-
trend=0.07). Following restriction to classical HL (n=127), although the results were still not 
statistically significant, the inverse association seemed to be strengthened (HRhigh vs. low= 0.57 
(95% CI: 0.30; 1.09), p-trend=0.09; HR1-unit increase=0.76 (95% CI: 0.55; 1.05), p-trend= 0.09) (data 
not shown). The results for the unclassified lymphoma (N= 395) as well as following restriction to 
lymphoma with known subtype classification did not modify materially the association (HR for a 1-unit 
increase in the arMED score: 0.98 (95% CI: 0.94; 1.03), p-value= 0.43, and 0.98 (95% CI: 0.96 to 1.00), p-
value= 0.04, respectively) (data not shown). 
No significant modifications in the association between lymphoma or its subtypes and the arMED 
score were observed for age, sex, and alcohol intake and smoking (Supplementary material, 
Table S1). Similarly, no significant differences were observed among countries (Supplementary 
material, Figure S1).  
In sensitivity analyses, including alcohol in the scoring did not affect the estimates for most of the 
lymphoma subtypes, although statistically significant associations were found for HL (HR1-unit 
increase=0.93 (95% CI: 0.86; 0.99), p-trend= 0.04)) and DLBCL (HR1-unit increase=0.96 (95% CI: 0.92; 
0.99), p-trend= 0.02)) (Supplementary material, Table S2).  Moreover, excluding the first 2 years 
of follow-up and those individuals with no information on adjustment variables from the analyses 
did not materially alter the results (data not shown). 
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4. Discussion 
This is the first prospective study to investigate the association between a Mediterranean dietary 
score and risk of lymphoma and its subtypes. Our findings suggest that a higher adherence to the 
MD is modestly associated with a lower risk of lymphoma.  
Current evidence on the adherence to MD and the etiology of lymphoma is scarce. To our 
knowledge, only one case-control study has evaluated the association of an a priori MD score 
and lymphoma, yielding no significant association for overall cases and only reporting an inverse 
association for DLBCL21. However, those results require cautious interpretation due to the 
retrospective study design, small sample size (322 cases for the particular subgroup analysis), 
and the use of a non-validated adaptation of the arMED score which did not include olive oil, 
white meat or dairy products. Other studies have extracted healthy-like dietary patterns from their 
population using data-driven analyses13–15, but also failed in finding patterns with all the MD 
features (e.g. none of them included olive oil). With the exception of the prospective study of 
Erber et al.14 who reported an inverse association between a pattern rich in vegetables and fruits 
and NHL among Caucasian women, none of the other case-control studies found any 
associations with overall HL15 or NHL13. However, given the heterogeneity in types of foods eaten 
within these patterns, the range and absolute amounts of food intakes and cut-offs used to define 
adherence, direct comparison of study results should be made with caution.  
Similarly, there is a lack of consistency for associations between questionnaire-derived dietary 
components and lymphoma risk. In the 2007 report by the WCRF/AICR22, the panel did not make 
any judgements regarding the causality of associations between specific dietary factors and 
lymphoid neoplasms. However, several suggestive associations were pointed out: i) vegetables, 
fruits, and alcoholic beverages were associated with decreased risk of lymphoma, ii) meat, total 
fat, and body fatness with increased risk of lymphoma, and iii) dairy products with increased risk 
of NHL. Although numerous studies have subsequently emerged, most of them targeted NHL 
patients, were mainly case-control studies and did not show consistent associations. Indeed, in 
the recently released third report of the WCRF/AICR, no additional information has been provided 
for hematological neoplasms5. Recent meta-analyses have shed light on this relationship: i) two 
meta-analyses found inverse relationships of vegetables and vegetables and fruit (combined) 
intake with NHL23,24, ii) another on foods of animal origin (including red, processed and white 
meat, fish and seafood, dairy products and eggs) reported positive associations with red meat 
and dairy intake and NHL25, iii) while cohort studies on specific micronutrients point to null 
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associations between supplemented vitamins A, C and E, total vitamin D intake, as well as 
dietary lycopene intake, and risk of NHL26. Overall, our results suggest that, more than specific 
dietary components, is the combined effect of a range of nutrients along with the putative 
biological interactions that take place between them that may be mediating the modest influence 
of adherence to the MD on lymphoma risk 
In an exploratory analysis, we observed strong inverse associations with HL albeit statistically 
non-significant. Given the small number of HL (N= 135), we may have lacked statistical power to 
detect significant associations within this subgroup. Previous studies of diet and HL risk are 
scarcer and limited in power6,7,15,21,27–34. Although no consistent associations have been reported 
for single-food items, the first study on dietary patterns and HL provided some insight15. The 
authors found a suggestive inverse association between a diet characterized by high intake of 
fruit and low-fat dairy products and mixed cellularity HL. In addition, positive associations were 
reported between Western-like patterns (rich in meat or desserts and sweets) and specific HL 
entities and age-groups. Together, these and our results suggest that HL might be a lymphoma 
prone to be influenced by dietary patterns. Thus, further studies with prospective design and with 
histological subtype-specific analyses, feasible though pooling data from consortium studies, are 
warranted.  
The original MD score included alcohol scored dichotomous variable12: two points were assigned 
for moderate consumers (5–25 g/day for women and 10–50 g/day for men) and 0 points for those 
above and below the sex-specific range, owing its beneficial effects if consumed in moderation. 
Convincing evidence suggests that alcohol increases the risk of several carcinomas (e.g. mouth, 
pharynx and larynx, esophagus, liver, colorectal, breast and stomach)5 and indeed, the 
WCRF/AICR recommendations currently promote lowering alcohol consumption5. However, 
accumulating evidence showed a moderate inverse association between increasing alcohol 
intake and NHL, especially on DLCBL and FL19. Thus, for the current analyses, alcohol was not 
included in the score, and models were adjusted and further stratified by alcohol intake. In 
sensitivity analyses, including alcohol in the score, statistically significant associations were found 
for HL and DLBCL. The influence of alcohol in lymphomagenesis remains largely unknown, and 
further studies are needed to clarify its role and possible interaction with dietary factors. 
Certain dietary features of the MD and their potentially anti-carcinogenic mechanisms make the 
association with lymphoma plausible from a mechanistic point of view. The abundance of plant-
based foods in the MD provides a diet rich in flavonoids, carotenoids, vitamin C or E, whose 
13 
 
important antioxidant properties can neutralize free radicals or prevent DNA damage22,35. Indeed, 
total antioxidant intake has been inversely associated with lymphoma36,37. Moreover, it presents  
a high monounsaturated to saturated fatty acid ratio, and its believed that circulating fatty acids 
may influence lymphoma risk by modulating inflammation or lymphocyte membrane stability38. In 
addition, several studies have consistently linked chronic inflammation or autoimmune conditions 
with lymphomagenesis3,39 and reported associations between plasma levels of cytokines, or other 
inflammatory markers, and lymphoma40–42. Recent studies are supporting the inflammatory 
potential of diet43; in particular for lymphoid neoplasms, positive associations have been recently 
reported between a pro-inflammatory dietary score and NHL44. Thus, the MD’s favorable fatty 
acid profile, as well as a high intake of fiber, vitamins and flavonoids, may be relevant owing its 
properties43.  
Interestingly, for the years 2000-2002, the incidence of total  lymphoid malignances, in particular 
HL, was higher in Southern Europe (Italy, Malta, and Spain) in comparison with other European 
regions45. We are not aware of studies that have attempted to correlate known risk factors for 
lymphoid neoplasms with regional variations in incidence. Further research on other dietary 
patterns (e.g. adherence to a Western-like or a pro-inflammatory diet) or the nutrition transition 
towards non-Mediterranean dietary patterns in many Mediterranean countries46 is warranted to 
elucidate these incidence patterns.  
Limitations of our study should be considered when interpreting the results, including potential 
measurement errors derived from dietary questionnaires, which could lead to systematic and 
random errors when estimating adherence to the MD. Although our adjustment for total energy 
intake would partly remove some of these errors47,48 we cannot rule out that they have affected 
risk estimates. In addition, we were unable to take into account any possible changes in dietary 
and lifestyle habits over time. In particular, cases might have modified their diet during the early 
prediagnostic period of the disease, although sensitivity analyses excluding incident cases 
diagnosed in the first 2 years of follow-up did not alter the association. Moreover, we lacked data 
on other potential confounders (e.g. occupational exposures or pesticide use) and, despite 
adjusting for all known lymphoma’s risk factors, residual confounding by other unmeasured or 
unknown exposure cannot be dismissed. In addition, given the number of comparisons 
performed, we cannot exclude chance findings. Moreover, despite the large number of enrolled 
subjects at baseline, the number of observed incident cases of some lymphoma subtype was low 
(e.g. 135 HL). Therefore, the study might not have sufficient power to detect significant 
associations within those subgroups.  Finally, the arMED score has also limitations, as similar 
14 
 
weight is given to each component and the foods within them, assuming that they have the same 
effects on health. However, according to current evidence, these groupings did not include dietary 
components which have distinct effects on lymphoma risk. In addition, the EPIC study included 
participants from both Mediterranean and non-Mediterranean regions, which may have distinct 
dietary intakes, food sources and socio-demographic, anthropometric and lifestyle characteristics 
that cannot be considered when using cohort-wide tertiles to construct the score. However, 
several studies have found similar associations’ when using study-wide or country-specific cut-
offs8,49 and no interactions were found by country in our study.  
The strengths of this study include its prospective design, long follow-up and large sample size 
which allowed us to carry out analyses by lymphoma subentities.  In addition, its multi-centric 
European design allowed the inclusion of a geographically diverse population, covering a wide 
range of dietary patterns and lifestyle habits. Finally, we assessed adherence to the MD with a 
widely-used score in cancer epidemiology, which directly includes olive oil intake, a key feature of 
this dietary pattern. Moreover, it uses tertiles of intake as cut-offs instead of the frequently used 
medians to give a better distribution of the subjects with different intakes. 
In summary, this is the first prospective study to examine the association between the MD and 
lymphoma risk. Our findings suggest that an increasing arMED score, reflecting adherence to the 
MD was modestly inversely associated with the risk of overall lymphoma. Further studies are 
needed to confirm these findings.  
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Supplementary material 
 
Table S1: Association between adherence to the arMED score and risk of lymphoma, HL, NHL and mature B-
cell NHL by sex, age, alcohol consumption and smoking in the EPIC study. 
Table S2: Association between adherence to the arMED score including alcohol and risk of lymphoma and its 
subtypes in the EPIC study. 
Figure S1: Association between adherence to the arMED score and risk of lymphoma, Hodgkin lymphoma and 
non-Hodgkin lymphoma by country in the EPIC study. 
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Table S1 
HR, hazard ratio; CI, confidence interval; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; DLBCL, diffuse large 
B-cell lymphoma; FL, follicular lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic leukemia; MM/PCN, multiple myeloma/ 
plasma cell neoplasm; Other B-cell (those cases for which the mature B-cell NHL subtype is unknown or does not fall within the more common 
subtypes) 
1 NHL subtypes, excluding 37 precursor NHL and 37 individuals with NHL without B- or T-cell information. 
2HR per 1-unit increase in the arMED; Cox proportional hazard model stratified by age (in 1-year categories), center and sex and further 
adjusted for body mass index, total energy intake, education, height, physical activity, smoking status, and alcohol intake. 
3P-value of Cox proportional model fitted with the arMED continuous variable. 
4P-value for interaction based upon the likelihood ratio (LR) test  
5Not estimated due to small sample size (1 failure). 
6Alcohol intake at recruitment categorized according to rMED categories for alcohol consumption: moderate (5–25 g/day for women and 10–50 
g/day for men), low (below the sex-specific range) and high (above the sex-specific range). 
In bold: p<0.05 
	
	
  
 Lymphoma 
(n=3,136) 
HL 
(n=135) 
NHL1 
(n=2,606) 
Mature B-cell 
(n=2,402) 
 HR2 (95% CI) P-value3 HR
2 (95% CI) P-value3 HR
2 (95% CI) P-value3 HR
2 (95% CI) P-value3 
Age         
<50 1.00 (0.96; 1.04) 0.93 0.93 (0.83; 1.06) 0.28 1.01 (0.96; 1.05) 0.80 1.00 (0.96; 1.05) 0.85 
50-75 0.98 (0.96; 0.99) 0.01 0.94 (0.84; 1.04) 0.21 0.98 (0.96; 1.00) 0.03 0.98 (0.96; 1.00) 0.05 
>75 1.19 (0.98; 1.46) 0.09 Not estimated5 - 1.23 (0.97; 1.57) 0.09 1.16 (0.91; 1.48) 0.23 
P-valueint4 0.79  0.21  0.53  0.59  
Sex         
Men 0.98 (0.96; 1.01) 0.21 0.98 (0.86; 1.11) 0.72 0.98 (0.95; 1.01) 0.20 0.98 (0.95; 1.01) 0.15 
Women 0.98 (0.96; 1.00) 0.08 0.90 (0.81; 1.00) 0.04 0.99 (0.96; 1.01) 0.27 0.99 (0.97; 1.01) 0.37 
P-valueint4 0.75  0.61  0.99  0.80  
Smoking status 
Never 0.98 (0.96; 1.00) 0.11 0.95 (0.84; 1.08) 0.42 0.98 (0.95; 1.01) 0.14 0.98 (0.95; 1.01) 0.12 
Former 0.99 (0.96; 1.02) 0.54 1.01 (0.87; 1.17) 0.89 0.98 (0.95; 1.02) 0.36 0.98 (0.95; 1.02) 0.34 
Current 0.98 (0.94; 1.01) 0.24 0.85 (0.74; 0.99) 0.03 1.00 (0.96; 1.05) 0.86 1.01 (0.97; 1.05) 0.74 
P-valueint4 0.15  0.41  0.86  0.90  
Alcohol intake (g/day)5 
Low 0.98 (0.96; 1.01) 0.20 0.94 (0.84; 1.04) 0.23 0.99 (0.96; 1.01) 0.37 0.99 (0.97; 1.02) 0.51 
Moderate 0.92 (0.86; 0.97) 0.004 0.94 (0.68; 1.28) 0.68 0.93 (0.87; 0.99) 0.02 0.92 (0.87; 0.99) 0.02 
High 0.99 (0.97; 1.02) 0.51 0.93 (0.81; 1.06) 0.28 0.99 (0.96; 1.02) 0.52 0.99 (0.96; 1.02) 0.46 
P-valueint4 0.08  0.58  0.24  0.10  
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Table S2  
  arMED score 
 
Low 
(0-7)  
Medium 
(6-10)  
High 
(11-18)  
P-value 
trend4 1-unit increase P-value
5 
 
Lymphoma, n 
 
1,016 
 
1,371 
 
  749    
HR1 (95% CI) Ref 0.95 (0.86; 1.03) 0.89 (0.78; 1.02) 0.09 0.98 (0.97; 1.00) 0.04 
HR2 (95% CI) Ref 0.95 (0.87; 1.04) 0.90 (0.79; 1.03) 0.13 0.99 (0.97; 1.00) 0.06 
 
HL, n 
 
39 
 
65 
 
31    
HR1 (95% CI) Ref 0.84 (0.54; 1.30) 0.64 (0.34; 1.21) 0.17 0.93 (0.86; 0.99) 0.03 
HR2 (95% CI) Ref 0.84 (0.54; 1.32) 0.64 (0.33; 1.22) 0.18 0.93 (0.86; 0.99) 0.04 
       
NHL, n 835 1,128 643    
HR1 (95% CI) Ref 0.95 (0.86; 1.04) 0.92 (0.79; 1.06) 0.20 0.99 (0.97; 1.00) 0.07 
HR2 (95% CI) Ref 0.95 (0.86; 1.05) 0.93 (0.80; 1.07) 0.27 0.99 (0.97; 1.00) 0.10 
 
NHL subtypes3       
 
Mature T/NK-cell, n 
 
47 
 
54 
 
29    
HR1 (95% CI) Ref 0.88 (0.57; 1.35) 1.10 (0.58; 2.09) 0.97 1.03 (0.96; 1.10) 0.48 
HR2 (95% CI) Ref 0.88 (0.57; 1.36) 1.14 (0.60; 2.19) 0.89 1.03 (0.96; 1.11) 0.43 
       
Mature B-cell, n 766 1,043 593    
HR1 (95% CI) Ref 0.95 (0.85; 1.05) 0.92 (0.79; 1.07) 0.23 0.98 (0.97; 1.00) 0.04 
HR2 (95% CI) Ref 0.95 (0.86; 1.05) 0.93 (0.80; 1.09) 0.31 0.98 (0.97; 1.00) 0.06 
 
DLBCL, n 
 
147 
 
245 
 
96    
HR1 (95% CI) Ref 1.02 (0.82; 1.27) 0.80 (0.56; 1.13) 0.35 0.96 (0.92; 0.99) 0.02 
HR2 (95% CI) Ref 1.04 (0.83; 1.29) 0.81 (0.57; 1.16) 0.43 0.96 (0.92; 0.99) 0.02 
       
FL, n 111 154 116    
HR1 (95% CI) Ref 1.00 (0.78; 1.29) 1.25 (0.88; 1.78) 0.30 1.01 (0.97; 1.05) 0.62 
HR2 (95% CI) Ref 1.00 (0.77; 1.30) 1.26 (0.88; 1.81) 0.28 1.01 (0.97; 1.05) 0.62 
       
CLL/SLL, n 182 213 142    
HR1 (95% CI) Ref 1.04 (0.84; 1.30) 1.00 (0.73; 1.38) 0.89 0.99 (0.96; 1.03) 0.78 
HR2 (95% CI) Ref 1.03 (0.83; 1.28) 0.99 (0.71; 1.37) 0.98 0.99 (0.96; 1.03) 0.66 
       
MM/PCN, n 226 283 167    
HR1 (95% CI) Ref 0.81 (0.66; 0.98) 0.85 (0.64; 1.14) 0.14 0.99 (0.96; 1.02) 0.57 
HR2 (95% CI) Ref 0.87 (0.65; 1.17) 0.87 (0.65; 1.17) 0.20 1.00 (0.96; 1.03) 0.82 
       
Other B-cell ,n 100 148 72    
HR1 (95% CI) Ref 0.90 (0.68; 1.18) 0.76 (0.50; 1.14) 0.19 0.96 (0.92; 1.00) 0.06 
HR2 (95% CI) Ref 0.90 (0.68; 1.20) 0.76 (0.50; 1.16) 0.22 0.96 (0.91; 1.00) 0.06 
       
HR, hazard ratio; CI, confidence interval; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; DLBCL, 
diffuse large B-cell lymphoma; FL, follicular lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic leukemia; 
MM/PCN, multiple myeloma/ plasma cell neoplasm; Other B-cell (those cases for which the mature B NHL subtype is unknown or 
does not fall within the more common subtypes). 
1HR per 1-unit increase in the arMED; Cox proportional hazard model stratified by age (in 1-year categories), center and sex and 
further adjusted for body mass index, total energy intake, education, height, physical activity, smoking status, and alcohol intake. 
4 
 
3NHL subtypes, excluding 37 precursor NHL and 37 individuals with NHL without B- or T-cell information. 
4P-value of Cox proportional model fitted with the arMED continuous variable. 
5P-value for interaction based upon the likelihood ratio (LR) test  
In bold: P-value<0.05 
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Figure  S1
 
HR, hazard ratio; CI, confidence interval; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular 
lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic leukemia; MM/PCN, multiple myeloma/ plasma cell neoplasm; Other B-cell (those cases for which the 
mature B NHL subtype is unknown or does not fall within the more common subtypes). 
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1HR per 1-unit increase in the arMED; Cox proportional hazard model stratified by age (in 1-year categories), center and sex and further adjusted for body mass index, total 
energy intake, education, height, physical activity, smoking status, and alcohol intake. 
2P-int: P-value for interaction based upon the likelihood ratio test. 3NHL subtypes, excluding 37 precursor NHL and 37 individuals with NHL without B- or T-cell information 
1 
 
Table and figure legend 
Table 1. Distribution of lymphoma cases in the EPIC study.  
Table 2. Baseline characteristics of participants in the EPIC study according to adherence to the arMED score. 
Table 3. Association between adherence to the arMED score and risk of lymphoma and its subtypes in the 
EPIC study. 
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Table 1  
 
        Lymphoma subtypes NHL subtypes1 Mature B-cell subtypes    
  Total cohort Person-years Overall  NHL HL NOS 
Mature B-
cell 
Mature T /NK-
cell    DLBCL FL CLL/SLL MM/PCN 
Other 
B-cell  
arMED  
mean (SD) 
Denmark 55,014 815,096.8 631 538 29 64  506 23  121 78 118 123 66 5.9 (2.4) 
France 67,403 869,362.5 228 216 11 1  205 8  40 44 44 45 32 8.5 (2.4) Germany 48,557 504,479.0 231 190 13 28 170 12 30 20 39 55 26 6.4 (2.1) 
Greece 26,048 281,283.6 62 44 3 15 38 2 3 3 13 15 4 11.8 (1.7) 
Italy 44,545 630,951.3 298 241 15 42 218 11 38 33 44 73 30 10.1 (2.1) 
Norway 33,975 452,171.1 163 147 5 11 129 14 26 31 26 24 22 7.7 (2.0) 
Spain 39,989 637,947.4 241 211 14 16 194 10 35 27 51 51 30 10.4 (2.2) 
Sweden 48,674 801,130.2 517 381 13 123 344 20 57 48 74 132 33 4.6 (2.1) 
The Netherlands 36,539 524,670.7 201 186 7 8 172 10 43 26 41 43 19 5.6 (2.1) 
United Kingdom 75,416 1,122,765 564 452 25 87 426 20 95 71 87 115 58 8.6 (2.5) 
Total 476,160 6,639,857.5 3,136 2,606 135 395   2,402 130   488 381 537 676 320 7.8 (3.0) 
NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; NOS, not otherwise specified; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic 
leukemia; MM/PCN, multiple myeloma/ plasma cell neoplasm; Other B-cell (those cases for which the mature B-cell NHL subtype is unknown or does not fall within the more common subtypes); arMED, adapted 
relative Mediterranean diet; SD, standard deviation. 
1There were 37 precursor NHL and 37 individuals with NHL without B- or T-cell information. 
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Table 2 
 
    arMED score 
  Total cohort Low (0-5) 
(mean 3.9)  
Medium (6-9) 
(mean 7.5)  
High (10-16)  
(mean 11.4) 
Total cohort, n 476,160 116,128 214,649 145,383 
Sex (%)     
Men 29.9 45.1 25.0 24.9 
Women 70.1 54.9 75.0 75.1 
Age at recruitment (mean [SD], years) 51.2 (9.9) 52.0 (10.0) 51.4 (9.5) 50.3 (10.4) 
Energy intake (mean [SD], kcal/day) 2,075.1 (619.2) 2,178.5 (648.0) 2,039.8 (604.1) 2,044.6 (608.6) 
Alcohol intake (median [25th-75th percentile], g/day) 5.3 (0.9; 14.9) 6.2 (1.4; 17.0) 5.6 (1.1; 15.2) 4.2 (0.4; 13.0) 
BMI (mean [SD], kg/m2) 25.4 (4.3) 25.6 (4.1) 25.1 (4.1) 25.8 (4.5) 
Height (mean [SD], cm) 166.0 (8.9) 169.6 (9.2) 165.9 (8.5) 163.2 (8.4) 
Smoking status (%)     
Never 49.0 41.5 49.2 54.5 
Former 26.6 27.7 27.7 24.3 
Current 22.4 29.6 20.8 19.0 
Unknown 2.0 1.24 2.3 2.3 
Physical activity (%)     
Inactive 21.0 17.6 18.1 27.8 
Moderately inactive 32.9 31.7 33.6 32.9 
Moderately active 26.4 25.2 28.4 24.3 
Active 17.9 22.3 17.8 14.5 
Unknown 1.85 3.2 2.0 0.5 
Educational level (%)     
None 4.4 0.5 2.4 10.5 
Primary school 25.6 30.2 22.4 26.6 
Technical/professional school 22.2 30.5 23.8 13.3 
Secondary school 20.4 17.1 21.9 20.9 
University 23.8 20.0 25.2 24.8 
Unknown 3.6 1.7 4.3 3.9 
BMI: body mass index; SD: standard deviation; arMED: adapted relative Mediterranean dietary score.	
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Table 3 
  arMED score 
  Low  Medium  High  
P-value  
trend4 1-unit increase 
P-value5 
Lymphoma, n 1,016 1,371   749    
HR1 (95% CI) Ref 0.92 (0.84; 1.01) 0.90 (0.79; 1.02) 0.08 0.98 (0.97; 1.00) 0.02 
HR2 (95% CI) Ref 0.93 (0.85; 1.02) 0.91 (0.80; 1.03) 0.12 0.98 (0.97; 1.00) 0.03 
 
HL, n 
 
39 
 
65 
 
31    
HR1 (95% CI) Ref 0.96 (0.61; 1.51) 0.64 (0.34; 1.18) 0.15 0.93 (0.86; 1.00) 0.07 
HR2 (95% CI) Ref 0.97 (0.61; 1.53) 0.64 (0.34; 1.19) 0.16 0.93 (0.86; 1.01) 0.07 
       
NHL, n 835 1,128 643    
HR1 (95% CI) Ref 0.90 (0.81; 0.99) 0.93 (0.81; 1.06) 0.23 0.98 (0.97; 1.00) 0.06 
HR2 (95% CI) Ref 0.90 (0.82; 1.00) 0.94 (0.82; 1.08) 0.31 0.98 (0.97; 1.00) 0.10 
 
NHL subtypes3       
 
Mature T/ NK-cell, n 
 
47 
 
54 
 
29    
HR1 (95% CI) Ref 0.73 (0.47; 1.13) 0.76 (0.42; 1.40) 0.31 0.99 (0.91; 1.07) 0.72 
HR2 (95% CI) Ref 0.72 (0.47; 1.14) 0.78 (0.42; 1.44) 0.35 0.99 (0.91; 1.07) 0.80 
       
Mature B-cell, n 766 1,043 593    
HR1 (95% CI) Ref 0.91 (0.82; 1.01) 0.94 (0.82; 1.08) 0.31 0.98 (0.97; 1.00) 0.08 
HR2 (95% CI) Ref 0.91 (0.82; 1.01) 0.95 (0.82; 1.10) 0.40 0.98 (0.97; 1.00) 0.11 
 
DLBCL, n 
 
147 
 
245 
 
96    
HR1 (95% CI) Ref 1.09 (0.87; 1.37) 0.83 (0.60; 1.14) 0.35   0.96 (0.92; 1.00) 0.07 
HR2 (95% CI) Ref 1.10 (0.88; 1.39) 0.84 (0.61; 1.17) 0.43     0.96 (0.93;1.01) 0.09 
       
FL, n 111 154 116    
HR1 (95% CI) Ref 0.84 (0.64; 1.11) 1.25 (0.90; 1.76) 0.19 1.02 (0.97; 1.07) 0.45 
HR2 (95% CI) Ref 0.84 (0.64; 1.11) 1.27 (0.90; 1.79) 0.17 1.02 (0.97; 1.07) 0.43 
       
CLL/SLL, n 182 213 142    
HR1 (95% CI) Ref 0.80 (0.64; 0.99) 0.95 (0.70; 1.27) 0.54 0.99 (0.96; 1.03) 0.75 
HR2 (95% CI) Ref 0.78 (0.63; 0.98) 0.92 (0.68; 1.25) 0.45 0.99 (0.95; 1.03) 0.64 
       
MM/PCN, n 226 283 167    
HR1 (95% CI) Ref 0.93 (0.77; 1.14) 0.98 (0.75; 1.28) 0.82 0.98 (0.95; 1.02) 0.40 
HR2 (95% CI) Ref 0.95 (0.78; 1.16) 1.01 (0.77; 1.34) 0.98 0.99 (0.95; 1.03) 0.55 
       
Other B-cell ,n 100 148 72    
HR1 (95% CI) Ref 0.85 (0.64; 1.13) 0.67 (0.45; 1.00) 0.05 0.96 (0.91; 1.00) 0.08 
HR2 (95% CI) Ref 0.85 (0.64; 1.14) 0.68 (0.46; 1.01) 0.06 0.96 (0.91; 1.00) 0.09 
arMED: adapted relative Mediterranean dietary score; n, number of cases; HR, hazard ratio; CI, confidence interval; HL, Hodgkin 
lymphoma; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; 
CLL/SLL, chronic lymphocytic leukemia/small lymphocytic leukemia; MM/PCN, multiple myeloma/ plasma cell neoplasm; Other B-cell 
(those cases for which the mature B NHL subtype is unknown or does not fall within the more common subtypes); arMED, adapted 
relative Mediterranean diet; SD, standard deviation. 
1Basic model: Cox proportional hazard model stratified by age (in 1-year categories), center and sex 
2Multivariate model: Cox proportional hazard model stratified by age (in 1-year categories), center and sex, and further adjusted for 
body mass index, total energy intake, educational level, height, physical activity, smoking status, and alcohol intake. 
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3 NHL subtypes, excluding 37 precursor NHL and 37 individuals with NHL without B- or T-cell information. 
4P-value of Cox proportional model fitted with the arMED ordinal variable as continuous to test for lineal trend. 
5P-value of Cox proportional model fitted with the arMED continuous variable. 
In bold: P-value<0.05 
